A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Trial Profile

A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Surotomycin (Primary) ; Vancomycin
  • Indications Clostridium infections; Diarrhoea; Intestinal infections
  • Focus Registrational; Therapeutic Use
  • Acronyms C-difficile
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 12 Apr 2016 Results assessing susceptibility and molecular epidemiology of Clostridium difficile presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
    • 12 Apr 2016 Primary endpoint of proportion of subjects with a clinical outcome of cure has not been met, according to results presented at the 26th European Congress of Clinical Microbiology and Infectious Disease.
    • 12 Apr 2016 Results presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top